This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The report indicates an uptick after five consecutive years of declining investment. In 2018, funding for HIV prevention R&D increased by a modest 1.2 percent or US$13 million from the previous year, growing to US$1.14 billion. While the increase is encouraging, it’s the smallest net increase since 2003.
Click here for the full archive of past resource tracking reports.
Civil society led by and for women in Africa is working with allies around the world to prepare for the ECHO results and advance a broader agenda of sexual health and rights that centers women and affirms the right to full information and informed choice, as well as integration of HIV and sexual and reproductive health programs. Reports from civil society forum meetings in 2018, as well as key resources, are available here.
A decade ago, UNAIDS and AVAC published the Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP). Created to provide a consistent global standard for stakeholder engagement across the research life-cycle, GPP has emerged as a point of reference for how to engage stakeholders. It has also given rise to a robust community of practice.
After ten years of implementation, AVAC offers a look back at GPP and a vision for its future — and we explain why GPP’s true potential lies in the hands not just of research groups, but of civil society, trials participants, and an array of stakeholders in the research endeavor.
As 2018 winds down, we’re struck by the many moments, and movements, in the past year that have depended on listening, without bias and also without loss of conviction. In that spirit, our year-end edition of Px Wire offers 10 questions for activists to pose, with curiosity and conviction, in 2019. What answers do you want, what do you hear, what needs to happen next?
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2017, reported funding for HIV prevention R&D decreased by 3.5 percent (US$40 million) from the previous year, falling to US$1.13 billion (Figure 2). This is the fifth consecutive year of decreasing annual investment, with 2017 levels representing the lowest funding since 2005.
Click here for the full archive of past resource tracking reports.
AVAC’s 2018 annual state of the field report, No Prevention, No End! looks at today’s prevention crisis and offers context, analysis and strategy to turn that crisis around.
In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a collaboration with the International AIDS Society’s (IAS) Towards an HIV Cure initiative to review and allocate grants towards HIV cure research and analyze data on global funding. The working group released a report in July 2018, Global Investment in HIV Cure Research and Development in 2017: After Years of Rapid Growth Funding Increases Slow.
This four-pager explores stories about stakeholder engagement in the current suite of efficacy trials as well as stories around global support for vaccine research in the age of an expanded HIV prevention landscape.
In the new issue of Px Wire, AVAC gives our take on this year’s PEPFAR process for establishing the Country Operational Plans (COPs). These plans define what work will be done with PEPFAR money at the country level and how that work will be evaluated in each of the 63 countries that receive PEPFAR money.
This short excerpt from our AVAC Report 2017 contains two stories: an update on hormonal contraception and HIV risk, including what to look out for in 2018, and an explanation of the damage caused by the Trump Administration’s expanded Global Gag Rule, preventing any organization receiving US global health funding from advocating for abortion as a family planning method.